Research & Treatments

Research

In 2007 a specific fund for?TTP?Education & Research?was set up as part of?University College London Hospital charitable fund; ?the proceeds of which to be?used for?further research into this rare disease.

If you wish to make a donation?direct to our JustGiving page, it would be greatly appreciated.

Otherwise, if?you prefer to donate by cheque, please make it payable to?UCLH charity No 0982?and post to:

Houda Webster
Haemostasis Research Unit
University College Hospital, 1st Floor, 51 Chenies Mews,
London WC1E 6HE

For those who can claim their donations against their taxes, please fill and return the attached Gift Aid form:

Gift Aid Declaration

Please?click here?for more information about our fundraising.

Plasma Exchange Therapy (Plasma pheresis) is recognised as the primary treatment for TTP. Plasma exchange should be commenced as soon as possible and continued for at least 7 days, regardless of how well the patient responds to treatment. Many patients need other forms of immunosuppression such as Steroids or Rituximab.

There are also some Congenital TTP patients who are given Factor VIII (8Y) as a treatment to keep their platelets stable. ?This is normally injected intravenously and can be done at home. ?This is hoped to be replaced through the use of a new treatment which is currently in the trial phase.

Click here to learn more about current trials and research which is being completed.

For up to date information on treatment guidelines for TTP, visit:

The British Committee for Standards in Haematology (BCSH)?and search for:

?Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias?

Alternatively click here for Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies